<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">

Using PDX as Surrogate Models for TME Investigation

Cancers are being increasingly recognized as collections of diverse immune diseases, on top of the genetic diversity already widely known. Disease aspects such as the heterogeneous tumor microenvironment and its immune components play a critical role in tumor growth, progression, and therapeutic/immunotherapeutic response, and therefore need to be fully investigated.